EGFR and Hyponatremia: According to a recent meta-analysis, the highest incidence (63.4%) of all-grade hyponatremia was observed in patients treated with Brivanib, a selective type 1 fibroblast growth factor receptor/vascular endothelial growth factor receptor-2 (VEGFR-2) antagonist combined with Cetuximab, a recombinant chimeric monoclonal antibody anti-EGFR (Her1).